U.S. Machinery Stock News

The Morning Bull - US Market Morning Update Tuesday, Jan, 13 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts down about 0.1%, as investors focus on three pressure points. First, December consumer price data is expected to show headline and core inflation at 2.7% year on year, a reading that will influence how quickly the cost of living is seen to be easing. Second, the 10 year US government bond yield is around 4.2%, reflecting higher borrowing costs for...

With a price-to-sales (or "P/S") ratio of 0.3x Green Plains Inc. ( NASDAQ:GPRE ) may be sending bullish signals at the...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Willis Lease Finance Corporation ( NASDAQ:WLFC ) shareholders have had their patience rewarded with a 25% share price...

While The Brink's Company ( NYSE:BCO ) might not have the largest market cap around , it saw a double-digit share price...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It hasn't been the best quarter for RF Industries, Ltd. ( NASDAQ:RFIL ) shareholders, since the share price has fallen...

IDEX Corporation ( NYSE:IEX ) stock is about to trade ex-dividend in 2 days. The ex-dividend date occurs one day before...

It's nice to see the Gibraltar Industries, Inc. ( NASDAQ:ROCK ) share price up 10% in a week. But if you look at the...

Gray Media, Inc. ( NYSE:GTN ), is not the largest company out there, but it saw significant share price movement during...

Despite an already strong run, FormFactor, Inc. ( NASDAQ:FORM ) shares have been powering on, with a gain of 32% in the...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$7.24 Apyx Medical is...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...

Wheels Up Experience (UP) is back in focus after receiving a NYSE notice about its sub US$1 share price, outlining cost reduction plans and expanding its Delta Air Lines partnership to let members book Delta flights through its portal. See our latest analysis for Wheels Up Experience. The NYSE notice and the expanded Delta partnership come after a sharp rebound in the 1 day share price return of 46.58% and a 7 day share price return of 44.45%. However, the 1 year total shareholder return...

Xometry (XMTR) is back in focus after announcing new high performance additive manufacturing materials, enhanced controls in its Instant Quoting Engine, and additional buyer options that closely align with aerospace, defense, and automotive needs. See our latest analysis for Xometry. At a share price of US$64.06, Xometry has seen a 10.45% 1 month share price return and 31.57% 3 month share price return. Its 1 year total shareholder return of 92.43% points to momentum that has been building...

In early January 2026, Wolfe Research downgraded Gulfport Energy Corporation from “Outperform” to “Peer Perform” after lowering its long-term US natural gas price assumptions, while US natural gas futures also fell to a 10-week low on warmer weather and softer heating demand. This combination of a more cautious analyst stance and weaker commodity pricing expectations has sharpened investor focus on Gulfport’s sensitivity to long-term natural gas fundamentals. We’ll now examine how Wolfe...

Xencor recently outlined its 2026 priorities and advancement milestones for its clinical-stage XmAb drug portfolio, highlighting progress across oncology and autoimmune programs, including early anti-tumor activity and tolerability for its lead T-cell engagers. An important takeaway for investors is Xencor’s expectation that its current cash resources should fund research and operations through 2028, supporting multiple planned pivotal studies without near-term financing guidance. We’ll now...

UroGen Pharma (URGN) shares are in focus after the company reported that its bladder cancer therapy ZUSDURI now has a permanent J code (J9282), effective January 1, 2026, simplifying reimbursement. See our latest analysis for UroGen Pharma. The J code news comes after a strong run for UroGen Pharma, with a 90 day share price return of 24.06% and a 1 year total shareholder return of 116.01%, signaling that momentum has been building rather than fading. If this kind of healthcare access story...

Rush Street Interactive recently reported third-quarter 2025 results that exceeded analyst expectations, delivered record revenue growth, and raised full-year guidance, while its CEO and CFO executed pre-arranged insider share sales following equity conversions and performance unit vesting. Despite these insider transactions, management’s stronger outlook and operational momentum suggest that trading-plan-driven sales may coexist with continued confidence in the company’s prospects. With...

In recent months, TopBuild has benefited from a construction surge, with its installer-distributor model capturing value from both material markups and installation services, helping it consistently exceed earnings estimates. This dual-revenue approach has allowed TopBuild to enhance margins while some manufacturers face cost pressure, highlighting how its business model can extract more value from robust building activity. We'll now examine how TopBuild's installer-distributor model,...

In January 2026, Rigel Pharmaceuticals issued full-year 2026 earnings guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenue. This fresh guidance gives investors a clearer view of how management currently sees the balance between core product sales and partnership-driven contract income. We’ll now consider how Rigel’s new 2026 revenue guidance,...